UK markets closed

NIKKEI 225
39,103.22
+486.12(+1.26%)
HANG SENG
18,868.71
-326.89(-1.70%)
CRUDE OIL
76.93
+0.06(+0.08%)
GOLD FUTURES
2,333.50
-3.70(-0.16%)
DOW
39,065.26
-605.78(-1.53%)
Bitcoin GBP
53,266.17
-1,213.67(-2.23%)

What does the UK general election mean for your finances?

Implications of a snap election on your pensions, savings, tax and investments

BLUE Nov 2024 1.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.3000

-0.0400

(-11.76%)

As of 01:16PM EDT. Market open.

GuruFocus.com
bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...
Detailed Analysis of Financial Performance and Future Outlook
Zacks
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Business Wire
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., May 09, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.